Altogen Biosystems is a biotechnology company dedicated to advancing biomedical research and therapeutic development. They are known for developing and supplying a wide range of sophisticated gene delivery reagents and transfection products, catering to diverse cell types and research applications. A key part of their operation is Altogen Labs, a GLP-compliant preclinical contract research organization (CRO). Altogen Labs offers extensive in vitro and in vivo study services, including specialized oncology xenograft models, pharmacology, and toxicology studies. Together, Altogen Biosystems and Altogen Labs aim to empower researchers in academic, pharmaceutical, and biotech sectors with high-quality tools and expert research support, accelerating the path from discovery to clinical application.
Serves as the main site for Altogen Labs' preclinical contract research operations, including in vitro and in vivo studies, sample analysis, and custom research project execution. R&D for new assays and models is also conducted here.
Features GLP-compliant laboratory facilities equipped for advanced molecular biology, cell culture, animal studies (including immunocompromised models), and bioanalytical services. Designed to support a broad range of preclinical research needs.
The Austin facility fosters a scientifically driven and collaborative work environment. Emphasis is placed on precision, quality, and adherence to rigorous scientific standards to deliver reliable data for clients' research and development programs.
This location in Austin, a significant and growing hub for biotechnology and life sciences, allows Altogen Labs to effectively serve its client base and contribute to the broader research ecosystem. It's central to their service delivery and R&D capabilities.
Altogen Biosystems serves a global market. Their specialized gene delivery reagents and transfection products are utilized by researchers in academic institutions, biotech companies, and pharmaceutical organizations worldwide. Altogen Labs' preclinical CRO services also cater to an international clientele, supporting drug development and biomedical research projects across different countries. While their physical labs are in the US, their reach is international through product distribution, service contracts, and collaborations.
11200 Manchaca Road, Suite 203
Austin
Texas
USA
Address: 848 Rainbow Blvd STE 823, Las Vegas, NV 89107
Provides a registered corporate presence in Nevada, facilitating business operations and compliance for Altogen Biosystems.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, ALTOGEN' leadership includes:
ALTOGEN has been backed by several prominent investors over the years, including:
As a privately held company, Altogen Biosystems does not typically publicize internal executive team changes unless they are of major significance. No prominent public announcements regarding executive hires or exits have been noted in the past 12 months.
Discover the tools ALTOGEN uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Altogen Biosystems likely utilizes standard professional email formats for its employees. Common patterns include combinations of first name, last name, and initials. For example, emails to Altogen Biosystems would use the @altogen.com domain, while communications related to Altogen Labs services might use @altogenlabs.com.
Likely formats include [first_initial][last]@altogen.com (e.g., jdoe@altogen.com) or [first].[last]@altogen.com (e.g., jane.doe@altogen.com).
Format
asmith@altogen.com (example, using first initial + last name)
Example
70%
Success rate
Accesswire via MarketWatch • March 19, 2024
Altogen Biosystems announced an expansion of its oncology contract research services, broadening its portfolio of over 100 validated cancer xenograft models. This initiative aims to bolster preclinical drug development by offering more comprehensive in vivo efficacy studies....more
Altogen Biosystems News • October 28, 2023
Altogen Biosystems featured its extensive selection of over 120 transfection reagents, optimized for a wide array of cell lines, including primary cells and those typically hard-to-transfect. These products support research in gene expression, RNA interference, and drug discovery....more
Altogen Biosystems News • March 7, 2023
Altogen Biosystems introduced a novel nanoparticle-based in vivo transfection reagent, engineered for efficient delivery of nucleic acids (such as plasmid DNA, shRNA, siRNA) directly to tissues in living animal models, enhancing preclinical research capabilities....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including ALTOGEN, are just a search away.